SMMT Shorts Ease as Earnings and FDA Decision Loom

Summit Therapeutics arrives at its October 27 earnings release with shorts quietly stepping back, options traders leaning toward calls, and a binary FDA decision on ivonescimab sitting just weeks beyond the print.

The positioning picture is unusually relaxed for a clinical-stage biotech with this much event risk. Short interest has eased to 5.4% of free float, around 41.9 million shares, down nearly 3% over the past week and off roughly 1.6% versus a month ago. That gentle bleed-off is the opposite of what bears typically do ahead of a print they expect to move against the stock. Borrow availability confirms the story: at 125%, shares available to lend comfortably exceed shares already borrowed, and cost to borrow has drifted down 9% on the week to 0.70%, its lowest level in over a month. There is no sign of a squeeze building, and no sign of aggressive fresh shorting either. The ORTEX short score, at 74, remains elevated as a composite measure of short-side pressure, but it has been edging lower all week from a high of 76.9 on October 20, a modest softening into the event.

Options traders are, if anything, modestly bullish. The put/call ratio is 0.63, a fraction below its 20-day average of 0.67 and sitting close to the lower end of its 52-week range of 0.42 to 1.21. At roughly 0.85 standard deviations below the recent mean, the skew points toward call buying rather than defensive hedging. The stock is down 10% over the past month to $15.47, but has bounced 6% across the past week, suggesting tactical positioning ahead of Monday's release rather than fresh selling pressure.

The analyst community is split, but the recent direction of travel has been upward. Jefferies upgraded to Buy in early September, lifting its target from $15 to $25. Citigroup, carrying a Buy rating, raised its target to $43 from $40 in late September. Barclays stayed at Equal-Weight but nudged its target to $20. The consensus mean target of $22.65 implies roughly 46% upside from Friday's close, though the range is wide and the bear cases are substantive. Bears focus on three specific concerns: the removal of a planned interim PFS analysis from the HARMONi-3 global study, final PFS data now not expected until the second half of 2026, and a November 14 FDA decision date for ivonescimab in non-small cell lung cancer. The toxicity profile in HARMONi-2, where Grade 3 or worse treatment-related adverse events ran at 29.4% versus 15.6% on the comparator arm, remains the central safety debate. Bulls counter that the market for a genuinely differentiated PD-1/VEGF bispecific is large enough to reward a clean efficacy read even against an increasingly competitive field anchored by Merck.

The ownership structure adds its own dimension to the setup. Co-CEO Robert Duggan holds 71.8% of shares outstanding, a grip that makes Summit one of the most founder-concentrated names in large-cap biotech. In June, both Duggan and co-CEO Mahkam Zanganeh made open-market purchases at $13.12 per share, each committing roughly $50 million in discretionary transactions with no 10b5-1 plan attached. CFO/COO Manmeet Soni also bought at similar levels. Those purchases, now sitting on a 18% gain, represent genuine conviction buys from the people closest to the pipeline data, though the stock has given back ground since an earlier peak.

Past earnings prints have been volatile. The August 2026 release produced a 3.7% next-day gain and a 15.9% move over five days. The July 2026 print went the other way, with the stock down 7.3% the next day and off 8.8% over the following week. The setup into Monday's release is therefore less about what the quarterly financials show, and more about what management says on the ivonescimab trial timeline, the HARMONi-3 interim data cadence, and any guidance around the November 14 FDA decision.

The key watch point heading into next week is the language around that FDA clock: any update on the PDUFA date, the completeness of the NDA submission, or early signals from the agency on the safety questions raised by the HARMONi-2 toxicity data will carry more weight than the quarterly cash burn figure.